Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has David F. McDermott's publication output changed over time?
ScholarIQpublication output · 2010–2018
Output grew0% over the shown period — from 1 works in 2010 to 1 in 2018.
1
1
2
1
1
20102012201420152018
What are the most-cited papers on David F. McDermott?
ScholarIQmost cited works
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi, Steven O’Day, David F. McDermott, Robert Weber, Jeffrey A. Sosman, John B.A.G. Haanen, René González, Caroline Robert, Dirk Schadendorf, Jessica C. Hassel, Wallace Akerley, Alfons J.M. van den Eertwegh, Jose Lutzky, Paul Lorigan, Julia Vaübel, Gerald P. Linette, David Hogg, Christian H. Ottensmeier, Célèste Lebbé, Christian Peschel, Ian Quirt, Joseph I. Clark, Jedd D. Wolchok, Jeffrey S. Weber, Jason Tian, Michael Yellin, Geoffrey Nichol, Axel Hoos, Walter J. Urba
New England Journal of Medicine. 201015,211 CitationsOPEN ACCESS
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer, Scott Gettinger, David C. Smith, David F. McDermott, John D. Powderly, Richard D. Carvajal, Jeffrey A. Sosman, Michael B. Atkins, Philip D. Leming, David R. Spigel, Scott Antonia, Leora Horn, Charles G. Drake, Drew M. Pardoll, Lieping Chen, William H. Sharfman, Robert A. Anders, Janis M. Taube, Tracee L. McMiller, Haiying Xu, Alan J. Korman, Maria Jure–Kunkel, Shruti Agrawal, D. G. McDonald, Georgia Kollia, Ashok Gupta, Jon M. Wigginton, Mario Sznol
New England Journal of Medicine. 201212,716 CitationsOPEN ACCESS
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst, Jean‐Charles Soria, Marcin Kowanetz, Gregg Fine, Omid Hamid, Michael S. Gordon, Jeffery A. Sosman, David F. McDermott, John D. Powderly, Scott Gettinger, Holbrook E. Kohrt, Leora Horn, Donald P. Lawrence, Sandra Rost, Maya K. Leabman, Yuanyuan Xiao, Ahmad Mokatrin, Hartmut Koeppen, Priti S. Hegde, Ira Mellman, Daniel S. Chen, F. Stephen Hodi
Nature. 20145,287 Citations
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Julie R. Brahmer, Christina Lacchetti, Bryan J. Schneider, Michael B. Atkins, Kelly Brassil, Jeffrey M. Caterino, Ian Chau, Marc S. Ernstoff, Jennifer M. Gardner, Pamela Ginex, Sigrun Hallmeyer, Jennifer Holter Chakrabarty, Natasha B. Leighl, Jennifer S. Mammen, David F. McDermott, Aung Naing, Loretta J. Nastoupil, Tanyanika Phillips, Laura Porter, Igor Puzanov, Cristina Reichner, Bianca Santomasso, Carole Seigel, Alexander I. Spira, María E. Suarez‐Almazor, Yinghong Wang, Jeffrey S. Weber, Jedd D. Wolchok, John A. Thompson
Journal of Clinical Oncology. 20183,719 CitationsOPEN ACCESS
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
Michael A. Postow, Jason Chesney, Anna C. Pavlick, Caroline Robert, Kenneth F. Grossmann, David F. McDermott, Gerald P. Linette, Nicolás Meyer, Jeffrey K. Giguere, Sanjiv S. Agarwala, Montaser Shaheen, Marc S. Ernstoff, David R. Minor, April K.S. Salama, Matthew H. Taylor, Patrick A. Ott, Linda M. Rollin, Christine E. Horak, Paul Gagnier, Jedd D. Wolchok, F. Stephen Hodi
New England Journal of Medicine. 20152,774 CitationsOPEN ACCESS
Related on ScholarIQ
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Paper
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
Paper
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Paper
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Paper
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
Paper
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
Paper